The company noted the findings in its first quarter earnings report, which said the teens experienced no serious side effects after receiving the shots. It noted that normal side effects, such as minor injection site pain, were similar to those in adults.
The 96% efficacy rate was reported in teens who had received at least one shot.
The company, founded in 2010, also reported the first quarterly profit in its history -- on
Sales of
"In the first quarter, the
"This accomplishment translated into our first profitable quarter in the company's history, after 10 years of scientific innovation and several billion dollars invested to make our mRNA platform a reality."
The earnings come a day after
The 50-microgram booster dose, which
The company said a booster shot of another COVID-19 vaccine, which was specifically matched against the
Drugmakers have said additional shots may be needed each year, similar to annual flu shots, to protect against variants.
"As we seek to defeat the ongoing pandemic, we remain committed to being proactive as the virus evolves," Bancel said in a statement.
"We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants."
Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source